Physician profile
Vincent D Smith
NPI 1912058579
$1,865.38
in general payments reported to CMS, 2019-2025
25 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $60.09 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.29 | 2019-2020 | |
| Novo Nordisk INC | $221.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $154.53 | 2019 | |
| Abbott Laboratories | $141.13 | 2025 | Esprit |
| Allergan, INC. | $133.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $131.74 | 2019-2020 | |
| Amgen INC. | $82.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.61 | 2019 | |
| Abbvie INC. | $65.23 | 2019 | |
| Amarin Pharma, INC. | $50.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.03 | 2019 | |
| Lundbeck LLC | $36.41 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.72 | 2019 | |
| Glaxosmithkline, LLC. | $26.06 | 2019 | |
| Antares Pharma, INC. | $17.72 | 2019 | |
| Genentech USA, INC. | $15.94 | 2019 | |
| Astellas Pharma US INC | $14.43 | 2019 | |
| Mannkind Corporation | $13.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2019 | |
| Assertio Therapeutics, INC. | $13.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.07 | 2019 | |
| Lilly USA, LLC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.